outperform price
earn model updat
report anoth strong quarter morn
top/bottom line beat well increas guidanc
year see chart within detail robust growth
throughout expect
ultomiri launch track well convers
far soliri enrol onesourc
continu expect convers end
seem well ahead schedul expect similar
soliri uptak mg continu strong
patient therapi us also
launch japan germani note good progress
japan slower growth germani continu
dodg question regard filing/launch strategi
territori base convers kol use
continu refractori patient
limit willing move earlier line
nmo regulatori decis come june pdufa
could anoth
larg opportun consensu
estim low launch challeng
expect burden relaps facil rapid uptak
setback fcrn inhibitor relat
impur correct anticip start
waiha gmg studi late year/earli
volunt data show igg lower
explor higher dose run-in
new ultomiri formul progress file
higher concentr reduc infus time
minut qw formul advanc also
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
partnership studi enabl
dose less
model updat updat earn revis
primarili driven reduct mg forecast
expect substanti deeper penetr beyond first
wave net effect pt move
track rel beat/miss
commentari around product serial around quarter includ
favor impact
million order ahead
unfavor impact
order time relat juli
favor impact
holiday tender
gmg continu
favor impact
tender offer
contribut gmg
continu grow
sale
convers april
includ order
unfavor impact
due order time
growth us germani
continu growth us
includ order
serial guidanc updat
non-gaap
non-gaap sg
margin total
addit commentari key programs/pipelin
nmo data ye
nmo data ye
applic earli
studi ultomiri
studi ultomiri ye
strong launch soliri
mg track becom
best soliri launch
patient drug march
mg launch track
patient treat jun
onesourc
launch first year
patient treat end
sept enrol
launch first year
patient treat end
patient treat end
march patient
soliri mid-april
present primari
endpoint met trend
toward superior
present primari
trend superior
submiss pnh mid
pnh eu
track file japan
on-going studi
children/adolesc
pnh children ahu
on-going studi
children/adolesc
pnh children ahu
data earli file
data earli file
ultomiri approv
enrol onesourc half
alreadi treat
submit us
initi studi
bioavail data
ultomiri approv
enrol onesourc
treat april
ahu file us
complet dose
studi
initi late
initi late
file cta eu
initi studi
initi
file late
initi mg studi
studi ye
plan initi poc studi
al ppm
plan initi poc studi
al ppm
increas trial size
power
superior plan file
trial power
superior file
data initi waiha
anoth pivot studi
plan initi studi
waiha gmg
issu encout
resolv plan initi
studi waiha
gmg late earli
complement pharma
dicerna
caelum
initi studi cael-
affibodi zealand
initi late
deriv valuat base dcf use discount rate appli
commerci stage biotech compani termin growth rate reflect optimist outlook durabl
compani franchis includ million product revenu reflect potenti busi
risk price target includ intensifi competit threat formid biopharma compani along potenti
amplifi price pressur failur build compel develop pipelin
articl articl
time dissemin april
analyst josh schimmer shenston huang maneka mirchandaney primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
